Correction to my post of Mar 01, 2023 01:13PM:

1) I believe what will be at play vis a vis the new publication, is the CORAL, a Phase 3 High-risk Covid-19 Outpatient Study stemming from the Type C meeting with the FDA.

https://www.resverlogix.com/investors/news?article=721

2) The post-COVID syndrome (long Covid) "associated with deleterious inflammatory responses will be the subject of future clinical evaluation."

https://www.resverlogix.com/investors/news?article=721

At least this is the way I see it playing out if in fact it actually plays out at all !

Koo